Updated:
Silo Pharma, Inc.
Silo Pharma researches investigational therapies and has disclosed cryptocurrency activities and October 2026 software and IP agreements.
Overview
Silo Pharma is a development-stage biopharmaceutical and cryptocurrency company. Its therapeutic research includes SPC-15, an intranasal candidate for post-traumatic stress disorder and stress-induced anxiety, and SP-26, a ketamine-based implant candidate for fibromyalgia and chronic pain. These programs remain investigational. In October 2026, Silo disclosed software and intellectual-property asset purchase agreements, adding a separate technology-related development to its therapeutic research activities. Its reported principal executive office is in Sarasota, FL (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 72,102; a net loss of USD 4,227,698; cash used in operations of USD 4,661,339. At that year-end, it reported total assets of USD 7,605,100 and cash and cash equivalents of USD 4,748,700.
Company overview
- Legal name
- Silo Pharma, Inc.
- Former names in filing history
- Uppercut Brands, Inc. (2019-08-13 to 2020-08-14); Point Capital, Inc. (2013-01-30 to 2019-05-14); Gold Swap Inc (2011-03-30 to 2013-01-07)
- Classification
- Public company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Sarasota, FL, United States
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 0001514183
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $72,102 | -$4.2M | $7.6M | $4.7M | -$4.7M | |
| FY2024USD | $72,102 | -$4.4M | $7.4M | $3.9M | -$3.8M | |
| FY2023USD | $72,102 | -$3.7M | $7.7M | $3.5M | -$3.2M | |
| FY2022USD | — | -$3.9M | $11.6M | $11.4M | -$3.5M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 10-Q | QUARTERLY REPORT | ||
| 8-K | CURRENT REPORT | ||
| DEF 14A | DEFINITIVE PROXY STATEMENT | ||
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 10-Q | QUARTERLY REPORT | ||
| 8-K | CURRENT REPORT |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Silo Pharma, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.